Risk of thrombophlebitis associated with continuous peripheral infusion of vancomycin: The effect of dilution
The Journal of Vascular Access · 2024-01 · 25 (1) · 107-112
DOI: 10.1177/11297298221095778 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Vascular Access, online erschienen am 24.05.2022. Verfasst von Marianna Scarano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Intensive Care 2 "A. Brienza," A.O.U. Policlinico "Giovanni XXIII," Bari, Italy. Hauptthemen laut MEDLINE: Catheterization, Peripheral, Thrombophlebitis, Venous Thrombosis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Introduction
Although several guidelines recommend that prolonged administration of vancomycin should be preferably carried out by a central venous access, vancomycin is often given peripherally. Whether such risk may be affected by different modalities of administration in terms of dilution and time of infusion, it is a matter of controversy.
Methods
This single-center prospective study enrolled all consecutive patients requiring prolonged intravenous infusion of vancomycin (1 g/day) using long peripheral cannula “mini-midline.” Patients were randomized in study group (4 mg/ml) and control group (20 mg/ml). All patients were systematically evaluated every 24 h by the Visual Exit-Site Score and a daily ultrasound scan of the veins of the arm.
Results
The daily ultrasound evaluation showed venous thrombosis at the distal tip of the cannula in all patients, in both groups. After this finding in the first 14 patients, the study was interrupted. All thromboses were completely asymptomatic and occurred in absence of any sign of catheter malfunction. The onset of thrombosis was significantly earlier in the control group (ranging from 24 to 48 h) than in the study group (ranging from 48 to 96 h), with an average of 30 ± 11 versus 68 ± 16 h ( p < 0.001).
Conclusion
Continuous intravenous infusion of vancomycin should be preferably delivered by a central venous access, as largely recommended by current guidelines, since peripheral infusion is inevitably associated with venous thrombosis, independently from the type of peripheral venous access device adopted (short peripheral cannula vs long peripheral cannula) and from the extent of dilution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesia and Intensive Care 2 "A. Brienza," A.O.U. Policlinico "Giovanni XXIII," Bari, Italy.
- Department of Anesthesia and Intensive Care, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Lazio, Italy.
- Department of Surgery, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
- Department of Infective Diseases, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
ORCID-Profile: Sonia D'Arrigo, Mauro Pittiruti
Zitieren
APA
Scarano, M., D'Arrigo, S., De Letteriis, S., Grasso, S., Pittiruti, M., & Scoppettuolo, G. (2024). Risk of thrombophlebitis associated with continuous peripheral infusion of vancomycin: The effect of dilution. The Journal of Vascular Access, 25(1), 107-112. https://doi.org/10.1177/11297298221095778
Vancouver
Scarano M, D'Arrigo S, De Letteriis S, Grasso S, Pittiruti M, Scoppettuolo G. Risk of thrombophlebitis associated with continuous peripheral infusion of vancomycin: The effect of dilution. The Journal of Vascular Access. 2024;25(1):107-112. doi:10.1177/11297298221095778
BibTeX
@article{Scarano2024,
author = {Scarano, Marianna and D'Arrigo, Sonia and De Letteriis, Sestilio and Grasso, Salvatore and Pittiruti, Mauro and Scoppettuolo, Giancarlo},
title = {Risk of thrombophlebitis associated with continuous peripheral infusion of vancomycin: The effect of dilution},
journal = {The Journal of Vascular Access},
year = {2024},
volume = {25},
number = {1},
pages = {107--112},
doi = {10.1177/11297298221095778}
}
EUVIMED